Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/02/26
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This YearThe Motley Fool • 01/30/26
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)Seeking Alpha • 01/24/26
AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term.The Motley Fool • 01/23/26
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos ExpansionSeeking Alpha • 01/23/26
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drugReuters • 01/22/26
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung CancerBusiness Wire • 01/20/26
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 01/16/26
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?Zacks Investment Research • 01/14/26
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)Business Wire • 01/12/26